Standard Engineering Technology Ltd
Q2 FY25 Earnings Call Analysis
Industrial Manufacturing
fundraise: No informationcapex: Yesrevenue: Category 2margin: Category 3orderbook: Yes
💰fundraise
Any current/future new fundraising through debt or equity?
- There is no explicit mention of any current or future fundraising through debt or equity in the call.
- The company highlights strong cash and cash equivalents of INR209 crores, providing significant financial flexibility.
- They emphasize disciplined management of working capital (173 days) and focus on strategic capital allocation.
- Management discusses planned capex of INR40-50 crores for existing facility upgrades and INR150-180 crores for a new greenfield project but does not specify funding sources.
- No plans for raising funds via equity or debt were indicated; the company relies on existing financial strength and internal accruals for expansions.
- They remain open to M&A if opportunities arise but provided no indication of requiring external funding for such activities.
🏗️capex
Any current/future capex/capital investment/strategic investment?
- Standard Glass Lining Technology Limited is investing INR40-50 crores over the next 1 to 1.5 years to mechanize and automate existing manufacturing facilities, including adding robots and upgrading processes.
- A new greenfield project is underway with planned capital expenditure of INR150-180 crores for a heavy engineering facility featuring 100 mm fabrication thickness and 110-ton crane capacity, expected to be completed in 15-18 months.
- The company is expanding capacity for shell and tube glass lining heat exchangers to produce up to 300 units monthly starting January 2026, to drive growth.
- Additional investments are planned to increase manufacturing capacity threefold, including automation, polishing, welding improvements, and new facility modifications.
- No major capex planned for the U.S. subsidiary in South Carolina; it will act mainly as a stock and service point initially.
- Future M&A opportunities will be considered if the right targets emerge.
📊revenue
Future growth expectations in sales/revenue/volumes?
- The company expects steady year-on-year revenue growth of 20% to 25% over the next several years.
- Driven by increasing enquiries, especially from Pharma CDMO clients, with no expected slowdown.
- Expansion in product lines, capacities, and automation efforts will support growth.
- New facility and capacity enhancements aim to nearly double revenue potential, targeting INR2,000 crores top line with current and new facilities combined.
- Export revenues expected to rise from current 13%-15% to 30%-40% in 5-6 years, enhancing overall growth and profitability.
- Shell and tube glass lining heat exchanger production capacity increasing to 300 units per month by early 2026, key growth driver.
- Continued strategic focus on high-margin product segments and international market penetration supports sustained volume growth.
📈margin
Future growth expectations in earnings/operating earnings/profits/EPS?
- Management expects steady year-on-year growth of 20% to 25% in revenue, driven by increased orders from Pharma CDMO and specialty chemicals sectors.
- EBITDA margin expansion was aided by better pricing, cost optimizations, and increased exports; export EBITDA contribution is around 25%.
- Export revenue is targeted to increase from 13%-15% currently to 30%-40% over the next 5-6 years, supporting margin improvement.
- Capacity expansions including automation and a new greenfield facility expected to triple manufacturing capacity are underway, enabling revenue potential of INR2,000 crores and beyond.
- Full-fledged sales of shell and tube glass lining heat exchangers starting June 2026 expected to drive growth and margins.
- Working capital days targeted to be reduced to 150 days to improve cash flows.
- Overall, management remains confident of maintaining 20%-25% revenue growth with sustainable EBITDA margins and enhanced profitability in coming years.
📋orderbook
Current/ Expected Orderbook/ Pending Orders?
- The company does not follow an order book disclosure philosophy and hence does not officially disclose the order book.
- For the current year, they mention being almost full in terms of order capacity ("this year, we are completely almost full").
- Order inflow from international markets is reported as very good this year.
- The company is experiencing increased enquiries and orders, especially from pharma and specialty chemicals sectors.
- They are planning significant capacity expansions to meet growing demand, including new facilities and automation.
- Shell and tube heat exchanger product line is expected to be a key growth driver starting full-fledged sales from June 2026.
